Quarterly report pursuant to Section 13 or 15(d)

Collaborative Arrangements - Textual (Details)

v3.19.3
Collaborative Arrangements - Textual (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
May 31, 2019
Dec. 31, 2018
Apr. 30, 2018
Oct. 31, 2017
Mar. 31, 2017
Aug. 31, 2015
Feb. 29, 2012
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2017
Dec. 31, 2016
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Total revenues               $ 21,906,000 $ 16,946,000 $ 49,808,000 $ 44,526,000    
Contract with customer, liability   $ 8,288,000           3,276,000   3,276,000      
Deferred revenue   4,936,000           1,288,000   1,288,000      
Research and Development Revenue [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Total revenues               11,555,000 8,541,000 25,220,000 26,235,000    
GSK [Member] | Technology Transfer, Collaboration and License Agreement [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Total revenues               2,000,000.0 0 2,000,000 0    
Contract with customer, liability               2,000,000.0   2,000,000.0      
GSK [Member] | Technology Transfer, Collaboration and License Agreement [Member] | Minimum [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
License revenue, contingent receivables                   5,750,000      
GSK [Member] | Technology Transfer, Collaboration and License Agreement [Member] | Maximum [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
License revenue, contingent receivables                   38,500,000      
Merck [Member] | Product [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Total revenues               3,600,000 3,400,000 11,400,000 10,700,000    
Merck [Member] | Collaborative Arrangement [Member] | Research and Development Revenue [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Total revenues               1,000,000.0 1,100,000 3,000,000.0 3,000,000.0    
Merck [Member] | Technology Transfer, Collaboration and License Agreement [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
License revenue, contingent receivables           $ 15,000,000.0              
Merck [Member] | Technology Transfer, Collaboration and License Agreement [Member] | Royalty [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Total revenues               0   0      
Merck [Member] | Merck Platform Technology Transfer and License Agreement, Protein Engineering [Member] | Collaborative Arrangement [Member] | Research and Development Revenue [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Total revenues               100,000   1,000,000.0      
Merck [Member] | Supply Agreement [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Optional extension period             5 years            
Contract with customer, liability   3,600,000           0   0      
Term of collaborative research and development agreement             5 years            
Merck [Member] | Supply Agreement [Member] | Research and Development Revenue [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Total revenues               0 0 0 1,300,000    
Customer [Member] | Supply Agreement [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Contract with customer, liability   2,000,000           2,000,000.0   2,000,000.0     $ 800,000
Fine chemical customer [Member] | Research and Development Agreement [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Contract with customer, liability         $ 3,000,000.0                
Term of collaborative research and development agreement         21 months                
Research and development revenue               0 1,300,000 50,000 7,100,000    
Nestec Ltd. (Nestle Health Sciences) [Member] | Global Development, Option and License Agreement [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Contract with customer, liability   1,900,000   $ 14,000,000.0       50,000   50,000      
Research and development revenue               100,000 3,700,000 1,800,000 8,100,000    
Nestec Ltd. (Nestle Health Sciences) [Member] | Global Development, Option and License Agreement [Member] | Milestone One [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Contract with customer, liability       4,000,000.0                  
Nestec Ltd. (Nestle Health Sciences) [Member] | Global Development, Option and License Agreement [Member] | Milestone Two [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Contract with customer, liability       1,000,000.0                  
Nestec Ltd. (Nestle Health Sciences) [Member] | CDX-6114 [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Cumulative catch-up adjustment to revenue, change in measure of progress                   3,000,000.0      
Nestec Ltd. (Nestle Health Sciences) [Member] | Collaborative Arrangement [Member] | CDX-6114 [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Milestone revenue   1,000,000.0                      
Nestec Ltd. (Nestle Health Sciences) [Member] | Collaborative Arrangement [Member] | Strategic Collaboration Agreement [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Contract with customer, liability                 600,000   600,000 $ 1,200,000  
Research and development revenue               1,400,000 $ 1,200,000 3,900,000 $ 2,400,000    
Deferred revenue   $ 800,000           25,000   25,000      
Nestec Ltd. (Nestle Health Sciences) [Member] | Research and Development Agreement [Member] | Maximum [Member] | Global Development, Option and License Agreement [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Milestone revenue       85,000,000.0                  
Nestec Ltd. (Nestle Health Sciences) [Member] | Sales-Based Milestone [Member] | Global Development, Option and License Agreement [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Target sales for sales milestone       1,000,000,000.0                  
Nestec Ltd. (Nestle Health Sciences) [Member] | Sales-Based Milestone [Member] | Maximum [Member] | Global Development, Option and License Agreement [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Milestone revenue       $ 250,000,000.0                  
Porton [Member] | Porton Agreement [Member] | Milestone One [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Contract with customer, liability     $ 500,000                    
Number of days for payment     30 days                    
Porton [Member] | Porton Agreement [Member] | Milestone Two [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Milestone revenue     $ 1,500,000                    
Novartis [Member] | Platform Technology Transfer and License Agreement [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Contract with customer, liability $ 5,000,000             1,200,000   1,200,000      
Term of collaborative research and development agreement 20 months                        
Research and development revenue               $ 3,800,000   $ 3,800,000      
Novartis [Member] | Platform Technology Transfer and License Agreement, Milestone One [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Contingent receivable $ 4,000,000                        
Novartis [Member] | Platform Technology Transfer and License Agreement, Milestone Two [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Contingent receivable 5,000,000                        
Novartis [Member] | Platform Technology Transfer and License Agreement Annual Technology Transfer [Member]                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Contingent annual receivable increase $ 8,000,000